

THERAPEUTIC AREA	INDICATION	NUMBER OF PATIENS	NUMBER OF SITES	STUDY DESIGN	CF RESEARCHER'S RESPONSIBILITIES	**
Dermatology	Acne vulgaris	76	1	Phase II	Protocol development, CRF Development, Site Management, Statistical analysis	C
Psychiatry	Insomnia	60	3	Phase III	Protocol development, CRF Development, Site Management, Statistical analysis	C
Psychiatry	Depression	120	4	Phase III	Protocol development, CRF Development, Site Management, Statistical analysis	C
Neurology	Ischemic stroke	151	5	Phase IV	Protocol development, CRF Development, Site Management, Statistical analysis	C
Oncology	lung cancer	*	*	Phase II	EC/RA submission, Site Management	T
Endocrinology/ Metabolism	Hyperlipidemia	100	5	Phase III	EC/RA submission, Site Management	C
Pulmonology	COPD	100	5	Phase III b	Site Management	=>
Dermatology	Psoriasis	240	7	Phase III b	Site Management	C
Psychiatry	Schizophrenia	14	4	Phase III b/IV	Site Management	C
Neurology	Migraine	60	5	Phase III	Site Management	C

Oncology	Lung cancer	12	2	Phase III	EC/RA submission, Site Management	=>
Oncology	Colorectal cancer	25	5	Phase II	EC/RA submission, Site Management	=>
Cardiovascular diseases	Coronary artery disease	80	8	Phase III	EC/RA submission, Site Management	=>
Endocrinology/ Metabolism	Diabetes	30	6	Phase II	EC/RA submission, Site Management	=>
Cardiovascular diseases	Chronic heart failure	120	6	Phase III	EC/RA submission, Site Management	=>
Neurology	Pain	30	3	Phase III	Site Management	=>
Endocrinology/ Metabolism	Diabetes	160	6	Phase III	EC/RA submission, Site Management	C
Vaccine	Influenza vaccine (paediatric)	120	6	Phase III	EC/RA submission, Site Management	=>
Endocrinology/ Metabolism	Gaucher disease	5	1	PMS	EC/RA submission, Site Management	=>
Pulmology	Idiopathic pulmonary fibrosis	10	2	Phase III	EC/RA submission, Site Management	=>
Psychiatry	Schizophrenia	24	3	Phase II	EC/RA submission, Site Management	=>
Neurology	Pain	30	3	Phase III	Site Management	C
Endocrinology/ Metabolism	Diabetes	124	9	Phase III	EC/RA submission, Site Management	C
Endocrinology/ Metabolism	Fatty liver	20	4	Phase III	EC/RA submission, Site Management	=>

Endocrinology/ Metabolism	Diabetes	18	2	Phase IV	EC/RA submission, Site Management	=>
Oncology	Colorectal cancer	65	7	Phase II	EC/RA submission, Site Management	=>
Pulmology	Idiopathic pulmonary fibrosis	2	3	Phase III	EC/RA submission, Site Management	=>
Endocrinology/ Metabolism	Diabetes	50	4	Phase III	EC/RA submission, Site Management	T
Cardiovascular diseases	Acute decompensated heart failure	46	11	Phase II b	EC/RA submission, Site Management	=>
Cardiovascular diseases	Venous thromboembolism	60	8	Phase III	EC/RA submission, Site Management	=>
Cardiovascular diseases	Thromboembolic events	15	3	Phase III	EC/RA submission, Site Management	=>
Psychiatry	Depression	24	4	Phase IV	EC/RA submission, Site Management	=>
Cardiovascular diseases	Thromboembolic events	37	3	Phase III	EC/RA submission, Site Management	=>
Psychiatry	Schizophrenia	121	8	Phase II	EC/RA submission, Site Management	=>
Oncology	Lung cancer			Phase III	Site Management	T
Cardiovascular diseases	Venous thromboembolism	30	4	Phase III	EC/RA submission, Site Management	=>
Psychiatry	Schizophrenia	22	1	Phase III/IV	EC/RA submission, Site Management	=>
Oncology	Squamous cell	16	3	Phase III	EC/RA submission,	=>

	carcinoma					
Endocrinology/ Metabolism	Obesity	36	5	Phase III	EC/RA submission, Site Management	=>
Hematology	Auto-immune thrombocytopenic purpura		2	Phase II	Rescue country	C
Cardiovascular diseases	Venous thromboembolism	120	5	Phase III	EC/RA submission, Site Management	=>
Psychiatry	Bipolar disorder	40	4	Phase IV	EC/RA submission, Site Management	C
Vaccine	Meningococcal vaccine (paediatric)	400	3	Phase III	EC/RA submission, Site Management	P
Psychiatry	ADHD	40	5	Phase IV	EC/RA submission, Site Management	P
Oncology	Breast cancer	80	7	Phase III	EC/RA submission, Site Management	=>
Endocrinology/ Metabolism	Fatty liver	20	4	Phase III	EC/RA submission, Site Management	=>
Cardiovascular diseases	Acute coronary syndrome	40	3	Phase II	EC/RA submission, Site Management	=>
Cardiovascular diseases	Venous thromboembolism	200	10	Phase III	EC/RA submission, Site Management	=>
Endocrinology/ Metabolism	Growth disorder	50	1	Phase III	EC/RA submission, Site Management	=>
Oncology	Multiple myeloma	16	2	Phase II	Site Management	=>
Oncology	Colorectal cancer		2	Phase III	EC/RA submission,	=>

					Site Management	
Endocrinology/ Metabolism	Hyperglycemia/Diabetes	115	3	Phase III	Site Management	=>
Neurology	Pain	20	3	Phase III	EC/RA submission, Site Management	C
Endocrinology/ Metabolism	Diabetes	120	4	Phase IV	EC/RA submission, Site Management	C
Neurology	SAH	30	3	Phase III	Site Management	=>
Cardiovascular diseases	Essential hypertension					P

** C – completed, P – planned, => on going, T – terminated